Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 1;85(4):243-247.
doi: 10.1097/FJC.0000000000001672.

Colchicine in Coronary Artery Disease: Where Do We Stand?

Aldo Bonaventura  1 , Nicola Potere  2 , Luca Liberale  3   4 , Simon Kraler  5   6 , Brittany N Weber  7 , Antonio Abbate  8
Affiliations
Review

Colchicine in Coronary Artery Disease: Where Do We Stand?

Aldo Bonaventura et al. J Cardiovasc Pharmacol. .

Abstract

Colchicine is an anti-inflammatory drug for different inflammatory conditions and is approved for secondary prevention of cardiovascular events in patients with coronary artery disease, mainly based on the results of the LODOCO2 and COLCOT trials. The recently published CLEAR SYNERGY trial reported neutral results for colchicine in patients with acute myocardial infarction undergoing percutaneous coronary intervention, challenging the previous reported benefits of colchicine. While colchicine appeared rather safe across the different studies, the variation in efficacy may suggest that the one-size-fits-all for the treatment of acute and chronic forms of coronary artery disease may not be appropriate, and that low-dose colchicine may be beneficial as an add-on therapy in patients who are stable or recovering from acute event, and not so helpful in patients with acute myocardial infarction already receiving intensive pharmaco-invasive therapies.

Keywords: acute myocardial infarction; cardiovascular disease; cardiovascular risk; colchicine; coronary artery disease.

PubMed Disclaimer

Conflict of interest statement

A. Abbate served as a consultant to Kiniksa, MonterosaTx, and Novo Nordisk. L. Liberale is coinventor on the International Patent WO/2020/226993 filed in April 2020. The patent relates to the use of antibodies that specifically bind IL-1α to reduce various sequelae of ischemia-reperfusion injury to the central nervous system. S. Kraler declares outside this work speaker fees from Roche Diagnostics and the Foundation for Cardiovascular Research—Zurich Heart House. Furthermore, he has received research grants to the institution from the Jubiläumsstiftung SwissLife, the Lindenhof Foundation, the Novartis Foundation for Medical-Biological Research, the Swiss Heart Foundation, the Swiss Society of Cardiology, and the Theodor-Ida-Herzog-Egli Foundation, and equipment and materials from Roche Diagnostics outside the submitted work. Travel support, again unrelated to this work, was received from the European Atherosclerosis Society, the European Society of Cardiology, the European Society of Clinical Investigation, Sphingotec GmbH, the 4TEEN4 Pharmaceuticals GmbH, and PAM Theragnostics GmbH. B.W. Weber reports scientific advisory board/consulting fees from Kiniksa, Novo Nordisk, BMS, and Horizon Therapeutics, outside of the submitted work. The other authors report no conflicts of interest.

References

    1. Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42:2745–2760.
    1. Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–410.
    1. Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61:1679–1685.
    1. Deftereos S, Giannopoulos G, Angelidis C, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation. 2015;132:1395–1403.
    1. Hennessy T, Soh L, Bowman M, et al. The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019;215:62–69.

MeSH terms

LinkOut - more resources